KPV Oral Tablets

KPV Oral Tablets Oral Delivery Profile

KPV Oral Tablets represents an advanced oral delivery system, engineered to survive gastrointestinal degradation and provide systemic biological activity without the need for traditional parenteral injection.

Pharmacological Architecture

Parameter	Value
Molecular Formula	C17H31N5O4
Molecular Mass	369.5 g/mol
Assay Purity	>99.0%
Appearance	Small white enteric-coated tablets

Figure 1: KPV Oral Tablets GI Tract Dissolution & Absorption

Oral Mechanism of Action

Detailed cascade of actions from ingestion to systemic effect:

1. Delivers the identical KPV (Lys-Pro-Val) anti-inflammatory tripeptide via an oral delivery vector.
2. Enteric coating dissolves exclusively in the alkaline environment of the small intestine.
3. Directly contacts the gut-associated lymphoid tissue (GALT) and intestinal epithelium.
4. Forces localized suppression of NF-kB activity within the inflamed intestinal mucosa.
5. Prevents mast cell degranulation and histamine release across the entire GI tract.

Figure 2: Rate of Oral Systemic Bioavailability

Primary Research Results

• Outcome 1: Premier oral compound for directly researching Irritable Bowel Disease (IBD) inflammatory cycles.
• Outcome 2: Dramatically reduces pro-inflammatory cytokines (IL-6, TNF-a) measured in stool biomarkers.
• Outcome 3: Provides localized gut healing without requiring systemic injection or absorption.

Oral KPV: Leveraging PepT1 Intestinal Transport

KPV oral tablets exploit a rare property among peptides: active intestinal absorption via the PepT1 (SLC15A1) oligopeptide transporter. PepT1 is a proton-coupled transporter densely expressed on the brush border membrane of duodenal and jejunal enterocytes. It recognizes di- and tripeptides for absorption, and KPV (Lys-Pro-Val) falls within its substrate specificity. This means KPV is one of the few bioactive peptides that can be administered orally with genuine mucosal bioavailability—particularly relevant for inflammatory conditions of the gastrointestinal tract where the target tissue is the intestinal epithelium itself.

1. PepT1 on the apical membrane of enterocytes recognizes and transports the KPV tripeptide into the intestinal epithelial cell via proton cotransport.
2. Inside the enterocyte, KPV directly inhibits NF-κB activation by blocking IκB kinase (IKK)-mediated phosphorylation of IκBα.
3. Local anti-inflammatory action occurs at the intestinal epithelial level before any systemic absorption, making oral KPV inherently gut-targeted.
4. PepT1 expression is paradoxically upregulated during intestinal inflammation (IBD), increasing KPV absorption precisely when it is needed most.
5. Absorbed KPV also enters the portal circulation and reaches the liver, where it can modulate hepatic NF-κB activity and Kupffer cell inflammatory responses.

Tablet Formulation & Research

• Enteric Coating: Tablets use acid-resistant coating to prevent gastric degradation and deliver intact KPV to the duodenum where PepT1 expression is highest.
• IBD Research: Oral KPV reduced colitis severity scores by 60–70% in DSS-induced murine colitis models, comparable to injectable administration.
• Convenience: Oral tablets eliminate the need for injection, reconstitution, and cold-chain storage, dramatically improving compliance in chronic administration research.
• Stability: The lyophilized tablet matrix protects KPV from oxidative degradation. Store at room temperature in sealed packaging; no refrigeration required.
• Dosing: Typical research protocols use 500 μg–1.5 mg per tablet, dosed 1–2 times daily. Taken on an empty stomach to maximize PepT1-mediated absorption.